vimarsana.com

இணைக்கப்பட்டுள்ளது மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AMA unit Health2047 spins out obesity testing startup to accelerate personalized medicine

Apr 1, 2021 12:02pm Phenomix Sciences blood-based test uses phenotype-driven multi-omics technology to predict responses to obesity interventions the Food and Drug Administration has approved. (vadimguzhva/GettyImages) The American Medical Association innovation subsidiary Health2047 has spun off a company that uses personalized medicine to fight obesity. Phenomix Sciences is a phenotype testing company that carries out the AMA’s mission to confront chronic diseases such as obesity. Phenomix uses a blood test called MyPhenome that it has licensed from the Mayo Clinic to allow doctors to prescribe individualized therapies. MyPhenome measures DNA as well as a person’s metabolites and hormones. These biomarkers make up a person’s phenotype, according to Phenomix.

A look at the diagnostics chapter of precision medicine

MedCity News A look at the diagnostics chapter of precision medicine More than 80% of representatives of health systems have established genomic data management strategies or plan to do so within the next couple of years. Shares0 Diagnostics are a critical part of precision medicine. They can be used to screen patients for breakthrough therapies, detect certain conditions, especially cancer, earlier. But this area of medical innovation is balanced between promising new developments in molecular diagnostics, genetic testing and liquid biopsies, the delivery of these tests, and the all important question of who pays for it. More than 80% of representatives of health systems have established genomic data management strategies or plan to do so within the next couple of years, according to a report by University of Pittsburgh Medical Center’s Center for Connected Medicine and HIMSS Media, which surveyed 101 health system and hospital representatives in the U.S. The report indicat

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.